12th May 2005 07:00
Deltex Medical Group PLC12 May 2005 Deltex Medical Group plc Radboud University Nijmegen Medical Centre adopts CardioQTM as a standard of care 12 May 2005: Deltex Medical Group plc ("Deltex Medical" or the "Company"), theAIM listed haemodynamic monitoring company, today announces that RadboudUniversity Nijmegen Medical Centre has become the first major universityteaching hospital in Europe to adopt its CardioQ cardiac function monitor as astandard of care in hospitals around the world. Following a six-month period of evaluation in both adults and childrenundergoing surgery, the hospital has entered into a contract with the Company'sdistributor in the Netherlands, MTT, to install six CardioQ monitors and twoCardioQPTM dedicated paediatric monitors. The contract specifies a target usageof up to 80 probes per month in this first phase of implementation. Andy Hill, Deltex Medical's Chief Executive, commented: "The adoption of ourproducts as part of routine surgical care at Radboud University Nijmegen MedicalCentre is a significant step forward in our goal to make haemodynamicoptimisation a standard of care across Europe and the rest of the world. "In the Netherlands, like much of the rest of Europe and in the US, patientsbenefit from a far higher level of post-operative care provision than in the UK.Nevertheless, doctors in Nijmegen have satisfied themselves that using theCardioQ can deliver significant clinical benefits and offers real opportunitiesfor improving efficiency and cost-effectiveness of care delivery." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, ChairmanAndy Hill, Chief ExecutiveEwan Phillips, Finance Director Financial DynamicsDavid Yates 0207 831 3113Lucy Briggs Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amountof circulating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- • validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works • proved that the CardioQ works in a wide range of surgical procedures • demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Deltex Medical